Antifibrinolytic hemostatic used in severe hemorrhage. .

Ugurol - Pharmacology:

Tranexamic acid competitively inhibits activation of plasminogen (via binding to the kringle domain), thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots, fibrinogen, and other plasma proteins, including the procoagulant factors V and VIII. Tranexamic acid also directly inhibits plasmin activity, but higher doses are required than are needed to reduce plasmin formation.

Ugurol Interactions

No information provided.

Ugurol Contraindications

CYKLOKAPRON Tablets and Injection are contraindicated:

  1. In patients with acquired defective color vision, since this prohibits measuring one endpoint that should be followed as a measure of toxicity.
  2. In patients with subarachnoid hemorrhage. Anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by CYKLOKAPRON in such patients.
  3. In patients with active intravascular clotting.

Generic name, Overdose, Half Life Ugurol, Food Interactions, Chemical, etc..

Ugurol see also

Brand Names containing Tranexamic Acid

Chemical structure:
N O O H H H H H H H H H H H H H H H C8H15NO2 2D chemical structure C8H15NO2 SVG | 2D structure Tranexamic Acid chemical names, chemical properties, classification C8H15NO2